4-((2R,3S,6S)-6-(4-Fluorophenyl)-3-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenol
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

2742940-92-54-((2R,3S,6S)-6-(4-Fluorophenyl)-3-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenol

● Under Development

Catalogue No.:VE009235
CAS No.:2742940-92-5
Mol. Formula:C18H19FO3
Mol. Weight:302.34 g/mol

Additional information on CAS 2742940-92-5

Parent drug

Ezetimibe

IUPAC Name

4-((2R,3S,6S)-6-(4-Fluorophenyl)-3-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenol

Smiles

OC1=CC=C([C@H]2[C@H](CO)CC[C@@H](C3=CC=C(F)C=C3)O2)C=C1

Synonyms

N/A

Description

4-((2R,3S,6S)-6-(4-Fluorophenyl)-3-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenol or 4-((2R,3S,6S)-6-(4-Fluorophenyl)-3-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenol, is an impurity present in Ezetimibe. Ezetimibe is reduces LDL-C, by selectively inhibiting intestinal cholesterol absorption. which is used to reduce the rate of cardiovascular events in high-risk patients. Ezetimibe is used in pharmacological lipid modification.

References

Hammersley, D., & Signy, M. (2016). Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic Advances in Chronic Disease, 8(1), 4–11. https://doi.org/10.1177/2040622316672544 ‌

Request a Quote

« * » indique les champs nécessaires

Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Products quotation
Name
Url